scholarly journals Obestatin controls the ubiquitin-proteasome and autophagy-lysosome systems in glucocorticoid-induced muscle cell atrophy

2017 ◽  
Vol 8 (6) ◽  
pp. 974-990 ◽  
Author(s):  
Tania Cid-Díaz ◽  
Icía Santos-Zas ◽  
Jessica González-Sánchez ◽  
Uxía Gurriarán-Rodríguez ◽  
Carlos S. Mosteiro ◽  
...  
2011 ◽  
Vol 112 (7) ◽  
pp. 1737-1748 ◽  
Author(s):  
Patricia Gonnella ◽  
Nima Alamdari ◽  
Steven Tizio ◽  
Zaira Aversa ◽  
Victoria Petkova ◽  
...  
Keyword(s):  

2017 ◽  
Vol 40 (5) ◽  
pp. 576-582 ◽  
Author(s):  
Hyunwoo Ju ◽  
Taewan Kim ◽  
Chan-Moon Chung ◽  
Junsoo Park ◽  
Takeshi Nikawa ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (7) ◽  
pp. e20202 ◽  
Author(s):  
Yuanjie Niu ◽  
Juan Wang ◽  
Zhiqun Shang ◽  
Shu-Pin Huang ◽  
Chih-Rong Shyr ◽  
...  

Author(s):  
Paul DeCosta ◽  
Kyugon Cho ◽  
Stephen Shemlon ◽  
Heesung Jun ◽  
Stanley M. Dunn

Introduction: The analysis and interpretation of electron micrographs of cells and tissues, often requires the accurate extraction of structural networks, which either provide immediate 2D or 3D information, or from which the desired information can be inferred. The images of these structures contain lines and/or curves whose orientation, lengths, and intersections characterize the overall network.Some examples exist of studies that have been done in the analysis of networks of natural structures. In, Sebok and Roemer determine the complexity of nerve structures in an EM formed slide. Here the number of nodes that exist in the image describes how dense nerve fibers are in a particular region of the skin. Hildith proposes a network structural analysis algorithm for the automatic classification of chromosome spreads (type, relative size and orientation).


2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.


Sign in / Sign up

Export Citation Format

Share Document